• WE ARE
    • We Are Early Phase
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • Management
    • Quality Principles
    • How we work
  • EARLY PHASE
    • First-in-Human
    • Interaction
    • Inhalation
    • Infusion & injection
    • Cardiac safety
    • PK/PD
    • Proof of Concept
    • Biosimilars
    • Vaccines
    • Bioequivalence
  • SERVICES
    • Development Consulting
    • Regulatory Consulting
    • Medical Writing
    • Data Management
    • Statistics
    • Multi-Site Service
    • Bioanalytics
  • PATIENT TRIALS
    • Diabetes
    • Obesity and Metabolism
    • Hypertension, Lipids, Inflammation, Endothelial Dysfunction
    • NAFLD/NASH
    • Dermatology
    • Endometriosis
    • Polycystic Ovary Syndrome
    • Medical Device Studies
    • Hemostaseology
    • Hepatology
    • Renal Impairment
    • Your individual request
  • SCIENCE
    • Our approach
    • Publications
  • CAREER
  • NEWS
  • WE ARE
    • We Are Early Phase
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • Management
    • Quality Principles
    • How we work
  • EARLY PHASE
    • First-in-Human
    • Interaction
    • Inhalation
    • Infusion & injection
    • Cardiac safety
    • PK/PD
    • Proof of Concept
    • Biosimilars
    • Vaccines
    • Bioequivalence
  • SERVICES
    • Development Consulting
    • Regulatory Consulting
    • Medical Writing
    • Data Management
    • Statistics
    • Multi-Site Service
    • Bioanalytics
  • PATIENT TRIALS
    • Diabetes
    • Obesity and Metabolism
    • Hypertension, Lipids, Inflammation, Endothelial Dysfunction
    • NAFLD/NASH
    • Dermatology
    • Endometriosis
    • Polycystic Ovary Syndrome
    • Medical Device Studies
    • Hemostaseology
    • Hepatology
    • Renal Impairment
    • Your individual request
  • SCIENCE
    • Our approach
    • Publications
  • CAREER
  • NEWS

Single-dose pharmacokinetics, safety, and tolerability of the dual endothelin receptor antagonist aprocitentan in subjects with moderate hepatic impairment.

Science
ShareTwitterFacebookXingLinkedin

You May Also Like

Science 30. Januar 2023
Bioequivalence of macitentan and tadalafil given as fixed-dose combination or single-component tablets in healthy subjects.
Science 30. Januar 2023
Midazolam microdosing applied in early clinical development for drug-drug interaction assessment.
Science 30. Januar 2023
The effects of vilaprisan on the pharmacodynamics and pharmacokinetics of a combined oral contraceptive – A randomized controlled trial.
QUICK LINKS
  • WE ARE
    • In a Nutshell
    • Our History
    • Facilities
    • Values
    • MANAGEMENT
  • EARLY PHASE
    • First-in-human
    • Cardiac safety
    • Infusion & injection
    • Inhalation
    • Pharmacology
    • Interaction
    • Consultancy
    • Medical Writing
    • Data Management
.
  • PATIENT TRIALS
    • Cardiometabolics
    • Dermatology
    • Women‘s Health
    • Hemostaseology
    • Hepatology
    • Pulmology
    • Renal Impairment
    • Vaccines
    • Your individual request
  • SCIENCE
  • WORK WITH US
EXPERTISE
  • Consultancy
  • Medical Writing
  • Early Phase
FACILITIES
  • Berlin
  • Kiel
  • Mannheim
  • Wuppertal
FÜR PROBANDEN
  • ÜBER STUDIEN
  • AN STUDIEN TEILNEHMEN
  • www.probandeninfo.de
LEGAL
  • PRIVACY
  • IMPRINT
  • DISCLAIMER
  • —
  • Career
    • CURRENT JOB
    • OPPORTUNITIES
Copyright © 2023 CRS. Experts. Early Phase. All rights reserved.